Anucaine Oral Suspension

Introduction

Anucaine is a prescription medication that combines three active ingredients: Oxetacaine, Aluminium Hydroxide, and Magnesium. It is commonly used to provide relief from symptoms associated with gastric hyperacidity, including heartburn, acid indigestion, and stomach ulcers.

Uses

Anucaine is prescribed to manage and alleviate symptoms of gastric hyperacidity. It can help reduce the production of stomach acid, relieve heartburn, and promote the healing of stomach ulcers.

Dosage and Administration

The recommended dosage of Anucaine may vary depending on the severity of the symptoms and the individual’s response to treatment. Follow the instructions provided by your healthcare professional. Generally, the medication is taken orally, usually after meals and at bedtime. Shake the bottle well before each use and use the measuring device provided to ensure accurate dosing.

Mechanism of Action

Anucaine contains three active ingredients that work together to alleviate symptoms of gastric hyperacidity. Oxetacaine acts as a local anesthetic, providing rapid relief from pain and discomfort. Aluminium Hydroxide and Magnesium work by neutralizing excess stomach acid, reducing its production, and protecting the lining of the stomach.

Side Effects

Common side effects may include constipation, diarrhea, nausea, and abdominal discomfort. These side effects are usually mild and temporary. However, if you experience any severe or persistent side effects, such as allergic reactions, difficulty breathing, or swelling of the face, lips, or throat, seek immediate medical attention.

Drug Interactions

inform your healthcare professional about all the medications you are currently taking, including prescription and over-the-counter medications, as well as any herbal supplements. Some medications, such as certain antibiotics, antifungals, and antacids, may interact with Anucaine and affect its effectiveness or increase the risk of side effects. Your healthcare professional will be able to advise you on any potential drug interactions.

Precautions

Before using Anucaine, inform your healthcare professional if you have any allergies to its ingredients or any other medications. Disclose any medical conditions you have, especially kidney problems or electrolyte imbalances. Anucaine should be used with caution in individuals with severe renal impairment. Additionally, avoid taking Anucaine within two hours of other medications, as it may interfere with their absorption.

Storage

Patient Tips

• Take Anucaine exactly as prescribed by your healthcare professional.
• If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Avoid consuming alcohol or tobacco while using Anucaine, as they may worsen gastric hyperacidity symptoms.
• If your symptoms persist or worsen despite using Anucaine, consult your healthcare professional for further evaluation and guidance.
• If you have any questions or concerns about using Anucaine, do not hesitate to reach out to your healthcare professional for clarification.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Polymorphic light eruption (NHS UK) [Accessed 9 Jun. 2024] (online) Available at:
• Boots Wind Relief Tablets (Health Professionals SmPC) Available at:
• Magnesium Hydroxide (International database) (Drugs.com) [Accessed 14 Jun. 2024] (online) Available at:
• magnesium carbonate capsule (RX/OTC) [Accessed 19 Jun. 2024] (online) Available at:
• Magnesium Hydroxide (MedlinePlus) [Accessed 13 Jun. 2024] (online) Available at:
• Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J, Kacew S, Lindsay J, Mahfouz AM, Rondeau V. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev. 2007;10 Suppl 1(Suppl 1):1-269. doi: 10.1080/10937400701597766. [Accessed 17 Jun. 2024] Available at: